There is a possibility of a novel new vaccine against Chikungunya virus, according to a clinical trial published in the Lancet Journal. The vaccine was based on a modified measles virus and two injections are enough to provide immunity. According to researchers at the University of Vienna, Austria, it facilitates production of antibodies, which neutralise the virus. The trials were conducted on 263 volunteers. Currently, there is no treatment which can halt the disease.